Pharmaceuticals, Biotechnology and Life Sciences
Futura Medical has filed a new formulation patent for its topical gel for the treatment of erectile dysfunction, with the UK Intellectual Property Office in connection with MED2002.
AB Science has recruited 350 patients for the phase 3 study (AB07015) in severe persistent asthma uncontrolled by oral corticosteroids, for which the final results will be available at the end of 2017.
Abzena, a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has reported that one of the ‘Abzena inside’ Composite Human Antibody products for the treatment of neurodegenerative conditions has moved to Phase II clinical trial.
Novartis has reported new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 90 to 100) following relapse during a treatment pause. Also showed no anti-secukinumab antibodies were observed during retreatment.
Novartis’s division Sandoz has reported that Phase 3 confirmatory efficacy, safety and immunogenicity study met its primary endpoint demonstrating biosimilar adalimumab GP2017 has equivalent efficacy to the reference medicine, Humira.
TiGenix has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and expects to receive a Marketing Authorization decision for Crohn’s disease drug Cx601 in 2017.
ALK has named Hendrik Nolte new R&D strategist in North America and International markets including China, and will work in collaboration with ALK’s partners for Russia, Japan, South-East Asia, Australia and New Zealand, Denmark-headquartered company said Friday.
Sanofi’s vaccines global business unit Sanofi Pasteur has signed a deal with AstraZeneca’s biologics bramch MedImmune, to make and sell a monoclonal antibody-called MEDI8897-for the prevention of the most common reason for lower respiratory tract infections in newborns and infants, Respiratory Syncytial Virus (RSV).
English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.
Swedish Orphan Biovitrum (Sobi) has received approval from the European Medicines Agency (EMA) for the grouped type II 15 K Variation for Elocta (efmoroctocog alfa), recombinant extended half-life factor VIII Fc fusion protein product for the treatment of haemophilia A.